Obesity is a public health problem that has reached epidemic proportions with an increasing worldwide prevalence. The global emergence of obesity increases the risk of developing chronic metabolic disorders. Thus, it is an economic issue that increased the costs of the comorbidities associated. Moreover, in recent years, it has been demonstrated that obesity is associated with chronic systemic inflammation, this status is conditioned by the innate immune system activation in adipose tissue that promotes an increase in the production and release of pro-inflammatory cytokines that contribute to the triggering of the systemic acute-phase response which is characterized by elevation of acute-phase protein levels. On this regard, low-grade chronic inflammation is a characteristic of various chronic diseases such as metabolic syndrome, cardiovascular disease, diabetes, hypertension, non-alcoholic fatty liver disease, and some cancers, among others, which are also characterized by obesity condition. Thus, a growing body of evidence supports the important role that is played by the inflammatory response in obesity condition and the pathogenesis of chronic diseases related.

Certainly, there was a mistake in the first publication [1]; however, consistently all analyses and results using the triglyceride and glucose (TyG) index have been performed with the following formula: Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)]/2. Several studies have used other formula, dividing by 2 the product of triglycerides and glucose, and after division, calculating the Ln. Obviously, the range of TyG values is different; however, they have consistently reported that TyG index is a reliable biomarker of insulin resistance. Regarding the usefulness of the TyG index in comparison with its components alone, a previous cohort study involving 43,197.32 person years revealed that TyG index exhibit a higher area under the curve (AUC = 0.75, 95% CI 0.70-0.81) than fasting plasma glucose (AUC = 0.66, 95% CI 0.60-0.72) and triglyceride levels (AUC = 0.71, 95% CI 0.65-0.77), resulting in a better predictor for the development of type 2 diabetes [2]. Additionally, another cohort study of 10-year follow-up demonstrated that TyG index is a better predictor for incident diabetes than triglycerides and fasting plasma glucose [3]. Evidence suggest that TyG index is a more effective biomarker than its separate components to identify glucose metabolism abnormalities; hence, the TyG index has been recommended as a screening tool of subjects at high risk of developing type 2 diabetes [2, 3].